Da Canal F, Breuer E, Hubel K, Mikulicic F, Buechel R, de Rougemont O
Ir J Med Sci. 2024; 193(6):2723-2732.
PMID: 39215777
DOI: 10.1007/s11845-024-03770-x.
Carta A, Tedesco M, Mescia F, Manenti C, Lucca B, Verzeletti F
Kidney Int Rep. 2024; 9(2):482-485.
PMID: 38344732
PMC: 10850993.
DOI: 10.1016/j.ekir.2023.11.009.
Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sarto G, Cosmai L
Clin Kidney J. 2024; 17(1):sfad290.
PMID: 38223338
PMC: 10784916.
DOI: 10.1093/ckj/sfad290.
Dobre M, Ahlawat S, Schelling J
Curr Opin Nephrol Hypertens. 2024; 33(2):203-211.
PMID: 38193308
PMC: 10872957.
DOI: 10.1097/MNH.0000000000000952.
Dorr K, Kammerlander A, Lauriero F, Lorenz M, Marculescu R, Beitzke D
J Cardiovasc Magn Reson. 2023; 25(1):62.
PMID: 37932788
PMC: 10626812.
DOI: 10.1186/s12968-023-00975-4.
FGF23 and klotho at the intersection of kidney and cardiovascular disease.
Edmonston D, Grabner A, Wolf M
Nat Rev Cardiol. 2023; 21(1):11-24.
PMID: 37443358
DOI: 10.1038/s41569-023-00903-0.
Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association.
Zoccali C, Mallamaci F, Adamczak M, Oliveira R, Massy Z, Sarafidis P
Cardiovasc Res. 2023; 119(11):2017-2032.
PMID: 37249051
PMC: 10478756.
DOI: 10.1093/cvr/cvad083.
Direct and indirect effects of fibroblast growth factor 23 on the heart.
Nakano T, Kishimoto H, Tokumoto M
Front Endocrinol (Lausanne). 2023; 14:1059179.
PMID: 36909314
PMC: 9999118.
DOI: 10.3389/fendo.2023.1059179.
Regulation of FGF23 production and phosphate metabolism by bone-kidney interactions.
Agoro R, White K
Nat Rev Nephrol. 2023; 19(3):185-193.
PMID: 36624273
DOI: 10.1038/s41581-022-00665-x.
Interaction of Vitamin D with Peptide Hormones with Emphasis on Parathyroid Hormone, FGF23, and the Renin-Angiotensin-Aldosterone System.
Latic N, Erben R
Nutrients. 2022; 14(23).
PMID: 36501215
PMC: 9736617.
DOI: 10.3390/nu14235186.
Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients.
Mark P, Mangion K, Rankin A, Rutherford E, Lang N, Petrie M
Clin Kidney J. 2022; 15(12):2186-2199.
PMID: 36381379
PMC: 9664574.
DOI: 10.1093/ckj/sfac146.
Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial.
Oka T, Sakaguchi Y, Isaka Y, Ishii H, Kabata D, Shintani A
Sci Rep. 2022; 12(1):15463.
PMID: 36104443
PMC: 9475027.
DOI: 10.1038/s41598-022-19820-2.
Interactions between FGF23 and vitamin D.
Razzaque M
Endocr Connect. 2022; 11(10).
PMID: 36040459
PMC: 9578066.
DOI: 10.1530/EC-22-0239.
Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.
Brandenburg V, Ketteler M
Nutrients. 2022; 14(15).
PMID: 35893866
PMC: 9330693.
DOI: 10.3390/nu14153009.
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study.
Binnenmars S, Hoogslag G, Yeung S, Brouwers F, Bakker S, van Gilst W
J Am Heart Assoc. 2022; 11(15):e024952.
PMID: 35876420
PMC: 9375507.
DOI: 10.1161/JAHA.121.024952.
Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of....
Dorr K, Hodlmoser S, Kammer M, Reindl-Schwaighofer R, Lorenz M, Reiskopf B
Front Med (Lausanne). 2022; 9:948177.
PMID: 35872799
PMC: 9299083.
DOI: 10.3389/fmed.2022.948177.
The Diabetic Cardiorenal Nexus.
DElia J, Bayliss G, Weinrauch L
Int J Mol Sci. 2022; 23(13).
PMID: 35806355
PMC: 9266839.
DOI: 10.3390/ijms23137351.
The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis.
Dorr K, Kammer M, Reindl-Schwaighofer R, Lorenz M, Marculescu R, Poglitsch M
Front Med (Lausanne). 2022; 9:878730.
PMID: 35559350
PMC: 9086596.
DOI: 10.3389/fmed.2022.878730.
Non-Additive Effects of Combined NOX1/4 Inhibition and Calcimimetic Treatment on a Rat Model of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Damrath J, Chen N, Metzger C, Srinivasan S, ONeill K, Biruete A
JBMR Plus. 2022; 6(3):e10600.
PMID: 35309859
PMC: 8914155.
DOI: 10.1002/jbm4.10600.
Left ventricular mass regression, all-cause and cardiovascular mortality in chronic kidney disease: a meta-analysis.
Maki K, Wilcox M, Dicklin M, Kakkar R, Davidson M
BMC Nephrol. 2022; 23(1):34.
PMID: 35034619
PMC: 8761349.
DOI: 10.1186/s12882-022-02666-1.
